Trial To Test Experimental Drug For Advanced Pancreatic Cancer
Cancer Research UK's Drug Development Office has launched a clinical trial* to test an experimental drug in patients with advanced (Stage IV) pancreatic cancer - one of the most difficult cancers to treat. Around 60 patients with advanced pancreatic cancer will be recruited for the first Phase I/IIclinical trial of a drug called MK-0752** in this disease...
Applications Open For New Carcinoid Tumor And Pancreatic Neuroendocrine Tumor Research Grants
The American Association for Cancer Research is pleased to announce new grant-giving partnerships with the Caring for Carcinoid Foundation (CFCF) and the Raymond and Beverly Sackler Fund for the Arts and Sciences. "The AACR is thrilled to partner with The Caring for Carcinoid Foundation and the Raymond and Beverly Sackler Fund for the Arts and Sciences," said Margaret Foti, Ph.D., M.D. (h.c...
Clavis Pharma Announces Recruitment Of The First Patients In Phase II Study Comparing CP-4126 With Gemcitabine In Pancreatic Cancer
Clavis Pharma (OSE: CLAVIS), the Norwegian cancer drug development company, and its partner Clovis Oncology, Inc. announce that the first two patients have been recruited into a Phase II clinical study comparing CP-4126 (also known as CO-1.01) with gemcitabine in the treatment of patients with pancreatic cancer...
Certain Cancers May Be Slowed By Alphavirus-Based Vaccine
An experimental vaccine based on a virus that causes encephalitis in the wild appears to block tumor growth in some cases of advanced cancer, according to researchers at Duke University Medical Center. Scientists say the vaccine is able to stimulate an immune response, even in the face of profound immune system suppression, a condition most patients with advanced cancer experience...
Advanced Pancreatic Cancer Patients May Benefit From Bacteriolytic Therapy
The aim of cancer immunotherapy is the stimulation of immune mechanisms to recognize malignant cells and may be a useful complementary therapy to conventional anticancer therapy. Immunotherapy was initiated over 100 years ago when New York surgeon William B. Coley inoculated a bacterial vaccine consisting of Streptococcus pyogenes and Serratia marcescens...
Fructose Encourages Pancreatic Cancer Growth
Pancreatic cancers use the sugar fructose, very common in the Western diet, to activate a key cellular pathway that drives cell division, helping the cancer to grow more quickly, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center has found...
Evaluation Of Pancreatic Cancer By Functional Magnetic Resonance Imaging
Pancreatic ductal adenocarcinoma (the disease commonly referred to as pancreatic cancer) carries the worst prognosis of any cancer. As current treatments offer minimal benefit, entirely new approaches are needed...
Seattle Genetics And Agensys, An Affiliate Of Astellas, Announce Initiation Of Phase I Clinical Trial Of ASG-5ME For Pancreatic Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors...
AmpliMed Reports Results From AMP-019; A Randomized Double Blind Trial Of Gemcitabine/Placebo Vs. Gemcitabine/Amplimexon In Advanced Pancreatic Cancer
AmpliMed Corporation, a cancer therapeutics company, announced results from AMP-019, a randomized double-blind, placebo-controlled Phase II screening trial designed to determine if a Phase III trial was warranted for the combination of gemcitabine (Gemzar, Eli Lilly) plus Amplimexon (AmpliMed Corporation) in patients with advanced pancreatic ductal adenocarcinoma of the pancreas...
Use Of Nanoparticles To Shrink Tumors In Mice Holds Important Implications For Cancer Therapy
The application of nanotechnology in the field of drug delivery has attracted much attention in recent years. In cancer research, nanotechnology holds great promise for the development of targeted, localized delivery of anticancer drugs, in which only cancer cells are affected...
Association Between Endoscopic Ultrasound Evaluation And Improved Outcomes In Pancreatic Cancer Patients
A new study has found that endoscopic ultrasound (EUS) is associated with improved outcomes in patients with localized pancreatic cancer, possibly due to the detection of earlier cancers and improved stage-appropriate management, including more selective performance of curative intent surgery...
Updated Guidelines On Cancer Care Published By ESMO
The European Society for Medical Oncology (ESMO) just released an enhanced and revised set of clinical recommendations designed to help oncologists deliver the best quality care to their patients...
Neogenix Oncology Files Patent Application For The 16C3 Antigen
Neogenix Oncology announced that the company has filed a patent application with the U.S. Patent and Trade Office (USPTO) for the 16C3 antigen. The Company believes that this antigen is tumor specific for pancreatic and colorectal tumors; and, based on preliminary clinical data, may also have diagnostic utility as a biomarker for these cancers...
Phase III Study Shows Novartis Drug Afinitor® More Than Doubles Time Without Tumor Growth In Advanced Pancreatic NET Patients
Novartis Pharmaceuticals Corporation ("Novartis") announced that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET)...
Study, Popular Diabetes Medications Not Associated With Increased Risk Of Acute Pancreatitis
Two popular diabetes drugs do not increase the risk of acute pancreatitis, according to a study presented today at the American Diabetes Association's (ADA's) 70th Scientific Sessions. The study conducted by Medco Health Solutions, Inc...
New Combination Effective Against Pancreatic Cancer
The new cancer medication sorafenib looks promising. Sorafenib is used for advanced liver and kidney cancer and also appears to be effective against cancer stem cells in pancreatic cancer. The team led by Professor Dr. Ingrid Herr, Head of the Department of Molecular Oncosurgery, a group of the Department of Surgery at Heidelberg University Hospital, (Managing Director: Professor Dr. Markus W...
Johns Hopkins Awarded $20 Million For Pancreas Cancer Research And Patient Care
Johns Hopkins Kimmel Cancer Center has been awarded the largest gift for pancreas cancer research in its history. The award was made possible by Albert P. "Skip" Viragh, Jr., a mutual fund leader, and a pancreas cancer patient treated at Johns Hopkins. He died of the disease at age 62. The funds formally establish the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care...
Detection And Removal Of Pancreatic Cysts May Lower Cancer Risk
Working with researchers from the University of Michigan and Indiana University, Van Andel Research Institute (VARI) investigators have developed a method that could be used to predict whether pancreatic cysts are benign or are precursors to invasive cancer. More pancreatic cysts are being detected due to the widespread use of high resolution abdominal imaging...
BSD Medical Reports Impressive Results From Clinical Study On Pancreatic Cancer Presented At ESHO 2010 Meeting
BSD Medical Corporation (NASDAQ: BSDM) reported impressive results from a clinical study on the use of hyperthermia, delivered using the BSD-2000 Hyperthermia System, to treat pancreatic cancer. Dr. S...
Targeted Immunotherapy: Metastatic Breast, Pancreatic Cancers
Early trials using targeted monoclonal antibodies in combination with existing therapies show promise in treating pancreatic cancer and metastatic breast cancer, according to research that will be presented by investigators from the University of Pennsylvania's Abramson Cancer Center at the 2010 meeting of the American Society of Clinical Oncology June 4 through 8...
Survival In Pancreatic Cancer Patients May Be Predicted By Response To Preoperative Therapy
Cancer of the pancreas - a glandular organ that lies behind the stomach and secretes vital enzymes and hormones - seldom is detected in early stages, making treatment difficult and survival statistics particularly grim...
Some Circulating Tumor Cells May Be Worse Than Others In Pancreatic Cancer Patients
Fox Chase Cancer Center investigators find that pancreatic cancer patients who have circulating tumor cells tend to have worse outcomes than patients without circulating tumor cells. Additionally, the team has uncovered evidence that not all circulating tumor cells are the same, and some may predict worse outcomes than others. Benjamin P. Negin, M.D...
Repligen Announces FDA And EMA Approval Of Re-analysis Of Images From Phase 3 Trial Of RG1068 For Pancreatic Imaging
Repligen Corporation (Nasdaq: RGEN) announced that the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved the Company's proposal to re-analyze the images from our Phase 3 study to establish the utility of RG1068, synthetic human secretin, in improving magnetic resonance imaging (MRI) of the pancreas (Phase 3 re-read)...
NewLink Initiates Pivotal Phase 3 Clinical Trial Of HyperAcute(R)-Pancreas Immunotherapy For Resected Pancreatic Cancer
NewLink Genetics Corporation announced treatment of the first patient in a nationwide Phase 3 clinical trial of its HyperAcute®-Pancreas cancer immunotherapy for patients who have successfully undergone pancreatic surgical resection...
Tumor-Targeted Rexin-G Prolongs Survival In Gemcitabine-Resistant Metastatic Pancreas Cancer In Advanced Phase I And II Studies (ASCO 2010)
Epeius Biotechnologies Corporation announces the results of the clinical study entitled "Phase I and II Studies of Intravenous Rexin-G as Monotherapy for Gemcitabine-resistant Metastatic Pancreas Cancer" at the ASCO Annual Meeting on June 6, 2010. The presentation will be discussed by Dr. Howard W. Bruckner, Bruckner Oncology, New York, NY...